The short version of ACTH fragment fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-22. Anything still debated is marked as such rather than presented as settled.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Seven-residue peptide |
| Molecular mass | 813.9 Da | Monoisotopic value |
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Freely soluble in water | Also soluble in saline and polar solvents |
| Storage (dry) | -20 °C or lower | Desiccated, protected from light |
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Vaginal estradiol is available in the forms of tablets, creams, inserts or suppositories, and rings. Vaginal estradiol tablets, creams, and inserts are usually administered once daily to twice weekly, whereas vaginal estradiol rings have a sustained action and are replaced once every 90 days. Vaginal estradiol can be used both as a systemic form of estradiol therapy, and at very low doses to selectively achieve a local vaginal effect without systemic effects, for instance in the treatment of menopausal symptoms such as vaginal atrophy and dryness. Vaginal estradiol is rapidly and almost completely absorbed. The absorption of vaginal estradiol is slightly greater in women with vaginal atrophy. Vaginal estradiol has high bioavailability and greatly increased potency compared to oral estradiol, with about 10- to 20-fold the comparative potency of oral estradiol. The greater potency of vaginal estradiol relative to oral estradiol is due to the lack of the first pass associated with oral estradiol and due to low local metabolism of estradiol in the vagina. Because of the high estradiol levels achieved, LH and FSH are more strongly suppressed with vaginal estradiol than with other routes. A daily dosage of 0.5 mg vaginal micronized estradiol has been found to result in estradiol and estrone levels of 250 pg/mL and 130 pg/mL, respectively. Vaginal estradiol has a much higher estradiol-to-estrone ratio in comparison to oral estradiol. The average ratio of estradiol to estrone with vaginal estradiol is 5:1, compared to 1:5 in the case of oral estradiol, a 10-fold difference.
Decarboxylation is a chemical reaction that removes a carboxyl group and releases carbon dioxide (CO2). Usually the term refers to a reaction of carboxylic acids, removing a carbon atom from a carbon chain. The reverse process, which is the first chemical step in photosynthesis, is called carboxylation, the addition of CO2 to a compound. Enzymes that catalyze decarboxylations are called decarboxylases or, more formally, carboxy-lyases (EC number 4.1.1).
==== Elution method ==== In order to elute His-tagged protein from the carrier there are several potential methods, which can be used in combination if necessary. In order to avoid denaturation of proteins, it is generally desirable to use as mild a method as possible.
Hormone transport and the involvement of binding proteins is an essential aspect when considering the function of hormones. The formation of a complex with a binding protein has several benefits: the effective half-life of the bound hormone is increased, and a reservoir of bound hormones is created, which evens the variations in concentration of unbound hormones (bound hormones will replace the unbound hormones when these are eliminated). An example of the usage of hormone-binding proteins is in the thyroxine-binding protein which carries up to 80% of all thyroxine in the body, a crucial element in regulating the metabolic rate.
Sources: en.wikipedia.org
=== Early life and career abroad === Zervas was born in 1902 in the rural town of Megalopolis in Arcadia, southern Greece. He was the first of 7 children of lawyer and parliamentarian Theodoros Zervas with Vasiliki Zerva (née Gyftaki). After finishing secondary education at the local Gymnasion of Kalamata in 1918, he went to study Chemistry at the University of Athens. Before finishing his studies there, he moved to Berlin in 1921 where he graduated with a degree in chemistry from the University of Berlin in 1924. Under the supervision of Max Bergmann, he finished his doctoral thesis on the reactions of amino acids with aldehydes and was awarded his Dr. rer. nat. from the University of Berlin in 1926. He proceeded to work with Bergmann in the Kaiser Wilhelm Institute for Leather Research in Dresden, of which Bergmann was the founder and director. From 1926 to 1929 Zervas was a research associate and eventually rose to head of the organic chemistry division and vice-director of the institute (1929–1934). It was at this period that the two men developed the Bergmann-Zervas oligopeptide synthesis which brought them international fame within academic circles. Zervas, by that point a close personal friend of Bergmann, decided to follow the latter to the US in 1934 after Bergmann emigrated from Nazi Germany in 1933 under pressure due to his Jewish origin. In New York, Zervas spent 3 years as lecturer and researcher at the Rockefeller Institute for Medical Research. In 1930, he married Hildegard Lange, and they remained together until his death.
=== Others === Unlike varenicline (brand name Chantix), naltrexone is not useful for smoking cessation. Naltrexone has also been under investigation for reducing behavioral addictions such as gambling, non-suicidal self-injury disorder, and kleptomania, as well as compulsive sexual behaviors in both offenders and non-offenders (e.g., compulsive porn viewing and masturbation). The results were promising. In one study, the majority of sexual offenders reported a strong reduction in sexual urges and fantasies, which reverted to baseline once the medication was discontinued. Case reports have also shown cessation of gambling and other compulsive behaviors, for as long as the medication was taken. When taken at much smaller doses, a regimen known as low-dose naltrexone (LDN), naltrexone may reduce pain and help to address symptoms of conditions other than those related to addiction. Reports have been published on the usefulness of LDN in the settings of ME/CFS, multiple sclerosis, fibromyalgia, and autoimmune diseases. Although its mechanism of action is unclear, some have speculated that it may act as an anti-inflammatory. As of October 2022, LDN was also being considered as a potential treatment for long COVID.
The brief existence of an mRNA molecule begins with transcription, and ultimately ends in degradation. During its life, an mRNA molecule may also be processed, edited, and transported prior to translation. Eukaryotic mRNA molecules often require extensive processing and transport, while prokaryotic mRNA molecules do not. A molecule of eukaryotic mRNA and the proteins surrounding it are together called a messenger RNP.
=== Additional views === Decubitus – taken while the patient is lying down, typically on their side. Useful for differentiating pleural effusions from consolidation (e.g. pneumonia) and loculated effusions from free fluid in the pleural space. In effusions, the fluid layers out (by comparison to an up-right view, when it often accumulates in the costophrenic angles). Lordotic view – used to visualize the apex of the lung, to pick up abnormalities such as a Pancoast tumor. Expiratory view – helpful for the diagnosis of pneumothorax. Oblique view – useful for the visualization of the ribs and sternum. Although it is necessary to do the appropriate adaptations to the x-ray dosage to be used.
Recurrences of the MFS at the site of surgery have developed in 16% to 57% of patients with a significant proportion (25%–52%) recurring multiple times. In one study, recurrences developed between 2 and 82 months (median 53 months) following primary surgery and metastatic disease developed in 23% of patients within 2 to 77 months (median 10 months) following primary surgery. Recurrent tumors tend to be more aggressive and have a much greater tendency to metastasize than primary MFS tumors. In one study, metastatic disease was detected in 23% of patients and occurred at a median of 10 months (range, 2–77 months) after resection of the primary tumor. In a review of multiple studies, the risk of developing metastases for lower grade MFS (defined in the following section) was <5% and for higher grade tumors was 25–30%. MFS metastasize most commonly to the lungs, bone, and lymph-nodes. Individuals with the epithelioid variant of FBS generally present with a tumor in the limbs; the tumors tend to be somewhat larger, more aggressive, and more likely to metastasize than the tumors in non-variant cases. At least 50% of patients with this variant have developed metastases.
Sources: en.wikipedia.org
=== Semiconductors === In 2014, researchers proved that they can create electrically conductive thin films of MOFs (Cu3(btc)2 (also known as HKUST-1; BTC, benzene-1,3,5-tricarboxylic acid) infiltrated with the molecule 7,7,8,8-tetracyanoquinododimethane) that could be used in applications including photovoltaics, sensors, and electronic materials and a path toward creating semiconductors. The team demonstrated tunable, air-stable electrical conductivity with values as high as 7 siemens per meter, comparable to bronze. Ni3(2,3,6,7,10,11-hexaiminotriphenylene)2 was shown to be a metal-organic graphene analogue that has a natural band gap, making it a semiconductor, and is able to self-assemble. It is an example of conductive metal-organic framework. It represents a family of similar compounds. Because of the symmetry and geometry in 2,3,6,7,10,11-hexaiminotriphenylene (hitp), the overall organometallic complex has an almost fractal nature that allows it to perfectly self-organize. By contrast, graphene must be doped to give it the properties of a semiconductor. Ni3(hitp)2 pellets had a conductivity of 2 S/cm, a record for a metal-organic compound. In 2018, researchers synthesized a two-dimensional semiconducting MOF (Fe3(THT)2(NH4)3, also known as THT, 2,3,6,7,10,11-triphenylenehexathiol) and showed high electric mobility at room temperature. In 2020 the same material was integrated in a photo-detecting device, detecting a broad wavelength range from UV to NIR (400–1575 nm).
On the day that it was inaugurated, two floors were being rented-out to businesses unrelated to Freemasonry. The tenth floor acted as the law offices of the law firm owned by the Grand Master, and to avoid commingling, when he needed to do business as a lawyer, he would sit in his office on the tenth floor, but when he needed to act as the Grand Master, he would walk upstairs to the Office of the Grand Master.
Diabetic retinopathy is an ocular pathology in diabetics which results in weakening of the retinal blood vessels. The initial nonproliferative stage is characterised by leaky vessels. As the vessel damage is repaired over time, they eventually become occluded, leading to proliferative diabetic retinopathy. The occluded capillaries create areas of ischemic retina and trigger the release of angiogenic growth factors. These growth factors stimulate the proliferation of new blood vessels from pre-existing retinal venules. It is the leading cause of blindness of working age adults.
Recipe Unlimited (previously known as Cara Operations) operates Harvey's, Swiss Chalet, Montana's Cookhouse, Kelsey's Neighbourhood Bar & Grill and other brands. The company also provides catering services to airlines. The revenue for its 1200 restaurants and its airline solutions division in 2008 was over $2 billion. Cara Airline Solutions operated about 10 flight kitchens across Canada that served more than 50 air carriers and rail travel customers, it was sold to Gategroup in 2010. Montana's Cookhouse started in 1995, was acquired by Cara in 2002, and operates 90 restaurants across Canada. There are 200 Swiss Chalet restaurants in Canada and the US. New York Fries is another Recipe Unlimited brand with about 200 stores in Canada, Hong Kong, UAE, Kuwait, and South Korea. New York Fries also had a burger company called South St. Burger, that sells burgers along with New York Fries and other products. It was spun off into a separate entity as part of the Cara acquisition. The largest Canadian-established hamburger chain in the nation, Harvey's was founded in Richmond Hill, Ontario, in 1959, it has franchises from Vancouver to St. John's, though most its restaurants are concentrated in southern Ontario and southern Quebec. On March 31, 2016, Cara announced that it would acquire the St-Hubert chain of rotisserie chicken restaurants in the summer of 2016. Recipe Unlimited also owns Prime Restaurants, the parent company of the restaurant chains East Side Mario's, Casey's, Pat and Mario's, Fionn MacCool's and Bier Markt Esplanade. Co-founded in Sudbury in 1980 by Bernard C.
Sources: en.wikipedia.org
It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.
The extension was introduced to slow enzymatic breakdown of the peptide in biological systems. Natural ACTH fragments are degraded rapidly by peptidases. Adding the tripeptide was intended to extend the window during which the molecule remains intact.
Most published work consists of animal experiments conducted in a small number of laboratories. Human data are limited in number and size. Whether the observed effects translate into reliable clinical benefit is still unresolved.
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.